- Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study2018 | Second Faculty of Medicine
- Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification2015 | Second Faculty of Medicine
- A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma2011 | Publication without faculty affiliation
- Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers2013 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine2010 | Second Faculty of Medicine
- The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples2022 | Second Faculty of Medicine
- Utilization of MLPA to detection of genetic changes in neuroblastoma2008 | Second Faculty of Medicine
- Chelators as Antineuroblastomas Agents2023 | First Faculty of Medicine
- Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials2018 | Second Faculty of Medicine
- Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study2018 | Second Faculty of Medicine
- Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study2020 | Second Faculty of Medicine
- Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)2021 | Second Faculty of Medicine
- Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial2017 | Second Faculty of Medicine